Dianthus Therapeutics, Inc. (DNTH)
82.37
-0.06
(-0.07%)
USD |
NASDAQ |
Oct 09, 16:00
83.00
+0.63
(+0.76%)
After-Hours: 20:00
Dianthus Therapeutics Gross Profit Margin (Quarterly) : 85.94% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 85.94% |
| March 31, 2026 | 83.59% |
| December 31, 2025 | 65.85% |
| September 30, 2025 | 75.00% |
| June 30, 2025 | 48.70% |
| March 31, 2025 | 88.56% |
| December 31, 2024 | 94.12% |
| September 30, 2024 | 94.66% |
| Date | Value |
|---|---|
| June 30, 2024 | 94.04% |
| March 31, 2024 | 87.76% |
| December 31, 2023 | 77.46% |
| September 30, 2023 | 97.94% |
| June 30, 2023 | 91.33% |
| March 31, 2023 | 82.98% |
| December 31, 2022 | 95.83% |
| September 30, 2022 | -103.2% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Verastem, Inc. | 89.92% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -25.87% |
| Return on Assets | -24.68% |
| Return on Invested Capital | -25.82% |
| Profit Margin (Quarterly) | -6.60K% |
| Operating Margin (Quarterly) | -8.08K% |
| Return on Net Operating Assets | -1.93K% |